title: Increased mature interleukin-1beta (IL-1beta) secretion from THP-1 cells induced by nigericin is a result of activation of p45 IL-1beta-converting enzyme processing.
abstract: Perregaux and Gabel (Perregaux, D., and Gabel, C. A. (1994) J. Biol. Chem. 269, 15195-15203) reported that potassium depletion of lipopolysaccharide-stimulated mouse macrophages induced by the potassium ionophore, nigericin, leads to the rapid release of mature interleukin-1beta (IL-1beta). We have now shown a similar phenomenon in lipopolysaccharide-stimulated human monocytic leukemia THP-1 cells. Rapid secretion of mature, 17-kDa IL-1beta occurred, in the presence of nigericin (4-16 microM). No effects on the release of tumor necrosis factor-alpha, IL-6, or proIL-1beta were seen. Addition of the irreversible interleukin-1beta-converting enzyme (ICE) inhibitor, Z-Val-Ala-Asp-dichlorobenzoate, or a radicicol analog, inhibited nigericin-induced mature IL-1beta release and activation of p45 ICE precursor. The radicicol analog itself did not inhibit ICE, but markedly, and very rapidly depleted intracellular levels of 31-kDa proIL-1beta. By contrast, dexamethasone, cycloheximide, and the Na+/H+ antiporter inhibitor, 5-(N-ethyl-N-isopropyl)amiloride, had no effect on nigericin-induced release of IL-1beta. We have therefore shown conclusively, for the first time, that nigericin-induced release of IL-1beta is dependent upon activation of p45 ICE processing. So far, the mechanism by which reduced intracellular potassium ion concentration triggers p45 ICE processing is not known, but further investigation in this area could lead to the discovery of novel molecular targets whereby control of IL-1beta production might be effected.
authors.affiliation: Novartis Pharma, CH-4002 Basel, Switzerland. Dominique.Cheneval@pharma.novartis.com
authors.forename: D
authors.initials: D
authors.lastname: Cheneval
authors.forename: P
authors.initials: P
authors.lastname: Ramage
authors.forename: T
authors.initials: T
authors.lastname: Kastelic
authors.forename: T
authors.initials: T
authors.lastname: Szelestenyi
authors.forename: H
authors.initials: H
authors.lastname: Niggli
authors.forename: R
authors.initials: R
authors.lastname: Hemmig
authors.forename: M
authors.initials: M
authors.lastname: Bachmann
authors.forename: A
authors.initials: A
authors.lastname: MacKenzie
mesh_terms: D000584:Amiloride / Q000494:pharmacology; D020170:Caspase 1; D002412:Cations; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D004789:Enzyme Activation; D006801:Humans; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D007476:Ionophores / Q000494:pharmacology*; D009550:Nigericin / Q000494:pharmacology*; D011188:Potassium / Q000378:metabolism; D011499:Protein Processing, Post-Translational; D014407:Tumor Cells, Cultured
chemical_list: D002412:Cations; D007375:Interleukin-1; D007476:Ionophores; D000584:Amiloride; D003546:Cysteine Endopeptidases; D020170:Caspase 1; D009550:Nigericin; D011188:Potassium